You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody biopolymer conjugate

Showing 1 - 25 of 6,534
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Neuroendocrine Carcinomas
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Wet Macular Degeneration Trial in Worldwide (KSI-301, Aflibercept, Sham Procedure)

Terminated
  • Wet Macular Degeneration
  • Phoenix, Arizona
  • +74 more
Jun 2, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Solid Tumor Trial in Worldwide (BYON3521)

Recruiting
  • Solid Tumor
  • Brussels, Belgium
  • +3 more
Aug 2, 2022

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Cancer Trial (Antibody-Drug Conjugate)

Not yet recruiting
  • Cancer
  • Antibody-Drug Conjugate
  • (no location specified)
Aug 23, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial (BN301)

Not yet recruiting
  • B-cell Lymphoma
  • +4 more
  • (no location specified)
Nov 9, 2022

Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +1 more
Jan 6, 2023

Multiple Myeloma Trial in Canton (STI-6129)

Recruiting
  • Multiple Myeloma
  • STI-6129
  • Canton, Ohio
    Gabrail Cancer Center
Jun 29, 2022

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

Pneumococcal Infections Trial in Jena (PCV13, PPV23)

Active, not recruiting
  • Pneumococcal Infections
  • Jena, Germany
    Center of Infectious Diseases and Infection Control, Jena Univer
Nov 9, 2022

Solid Tumor Trial in Brussels, Bordeaux, Lille (SYD1875)

Active, not recruiting
  • Solid Tumor
  • Brussels, Belgium
  • +2 more
Jan 12, 2022

Cancer, Cancer, Lung Trial in Fairfax (CPO301)

Recruiting
  • Cancer
  • Cancer, Lung
  • Fairfax, Virginia
    NEXT Virginia
Jul 10, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Advanced NSCLC Trial in United States (REGN5093-M114)

Recruiting
  • Advanced NSCLC
  • Aurora, Colorado
  • +7 more
Aug 11, 2022

Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)

Active, not recruiting
  • Solid Tumor
  • SYD985 + Niraparib
  • Antwerp, Belgium
  • +5 more
Jan 23, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer Trial in United States (STRO-002, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Tampa, Florida
  • +5 more
Aug 1, 2022

Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

Recruiting
  • Breast Neoplasms
  • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 30, 2022

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023